•  
  •  
 

Corresponding Author

Ahmed Radwan Hegy

Abstract

Background: Osteocytes increase the production of fibroblast growth factor 23 (FGF23) as a result of the inflammatory response associated with active lupus. Consequently, lupus nephritis (LN) patients are typically characterized by a significantly elevated level of FGF23 in comparison to SLE patients who do not have nephritis.

Aim: To assess the serum levels of FGF23 in nephritis patients and without nephritis.

Methods: This prospective case-control study was conducted on 60 participants aged > 18 years and <50 years. Cases were divided into three equal groups: Group 1: SLE with LN. Group 2: SLE without LN. Group 3: (Control group): healthy age-matched individuals.

Results: There was a significant difference among the studied groups regarding ISN/RPS classes, activity index, and chronicity index. The lupus without nephritis (NN) group had a significant increase in hematuria compared to other groups. Proteinuria grade +++ and Casts were more prevalent in the LN group than in the NN group. The 24-hour urinary protein was significantly elevated in the LN group. Platelet was significantly lower in the LN group compared to other groups. The LN group showed a significant decrease in the total and ionized Ca level with a significant increase in PO4 level compared to other groups. FGF23 was significantly elevated in the LN group in contrast to the other groups.

Conclusions: Systemic lupus erythematosus cases with LN exhibited higher FGF23 serum level than patients without LN and further assessment is needed to detect if it can be used as a biological marker for nephritis.

Article Type

Original Article

Keywords

Fibroblast Growth Factor 23; Lupus Nephritis

Subject Area

Rheumatology and Medical Rehabilitation

Download

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 1
    • Downloads: 1
see details

Share

COinS